NRX Pharmaceuticals (NRXP) Equity Income (2026)
NRX Pharmaceuticals' (NRXP) quarterly Equity Income came in at $3000.0 in Q2 2026, up 50.0% quarter-over-quarter from $2000.0 in Q1 2026.
Powered by 
Analysis
NRX Pharmaceuticals (NRXP) Equity Income (2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Equity Income for 1 consecutive years, with $3000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Equity Income changed N/A year-over-year to $3000.0 in Q2 2026; TTM through Jun 2026 was $5000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $35000.0, changed N/A from the prior year.
- Equity Income was $3000.0 for Q2 2026 at NRX Pharmaceuticals, up from $2000.0 in the prior quarter.
- Over five years, Equity Income peaked at $3000.0 in Q2 2026 and troughed at $2000.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | NRX Pharmaceuticals | 127.63 Mn | 100.93 Mn | 426,000.00 | 3,000.00 |